Jessica Meisenhelder, NP
Family · Goldsboro, NCNPI 1447768502
Payments from drug & device makers
Across 58 payments — averaging $36.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Johnson & Johnson$67
- Seagen Inc.$67
- Merck$64
- Recordati_rare_diseases_inc.$56
- Daiichi Sankyo Inc.$54
- plus $511 from 21 others
What the payments were for
- Food & beverage$79537%
- Education$673%
- Other$1,28060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $1,322 |
| Johnson & Johnson | 4 | $67 |
| Seagen Inc. | 1 | $67 |
| Merck | 3 | $64 |
| Recordati_rare_diseases_inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Bristol Myers Squibb | 2 | $43 |
| Bayer | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| AbbVie | 2 | $32 |
| Karyopharm Therapeutics Inc. | 2 | $31 |
| Acrotech Biopharma Inc. | 2 | $31 |
| Array Biopharma Inc | 2 | $30 |
| Astellas Pharma US Inc | 2 | $30 |
| Incyte Corporation | 2 | $30 |
| Genmab U.S., Inc. | 1 | $28 |
| Taiho Oncology, Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| AstraZeneca | 1 | $20 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Novocure Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Gilead | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
How this compares
$2,142 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 50 | $30,130 |
| Exemestane | 18 | $5,220 |
| Anastrozole | 53 | $1,313 |
| Ondansetron Hcl | 51 | $1,043 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $974 |
| Tamoxifen Citrate | 21 | $773 |
| Morphine Sulfate ErMorphine Sulfate | 17 | $624 |
| Hydroxyurea | 23 | $601 |
| Oxycodone Hcl | 17 | $542 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $525 |
| Gabapentin | 33 | $376 |
| Promethazine Hcl | 40 | $332 |
| Pregabalin | 14 | $250 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 17 | $226 |
| Methylprednisolone | 19 | $132 |
Paid to pharmacies, not to this prescriber.
Other family in Goldsboro
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.